ANKRD13a controls early cell-death checkpoint by interacting with RIP1 independent of NF-κB

Area of Science:

• Cellular biology
• Molecular oncology
• Immunology

Background:

• Tumor necrosis factor (TNF) signaling regulates cell survival and death.
• Ubiquitination of Receptor-Interacting Protein 1 (RIP1) is crucial for controlling TNF-induced cell death.
• The transition from complex-I to complex-II dictates the cell fate in TNF signaling.

Purpose of the Study:

• To identify novel regulators of TNF-induced cell death.
• To investigate the role of ankyrin repeat domain 13a (ANKRD13a) in TNF signaling.
• To explore the clinical relevance of ANKRD13a in ovarian cancer.

Main Methods:

• Investigated ANKRD13a's function in TNF signaling pathways.
• Utilized cell-based assays to examine complex-II formation and cell death.
• Analyzed ANKRD13a expression in ovarian cancer tissues and correlated it with patient outcomes.

Main Results:

• ANKRD13a acts as a novel component of complex-II, raising the threshold for TNF-induced cytotoxicity.
• ANKRD13a deficiency promotes complex-II formation and shifts TNF response from survival to death.
• ANKRD13a binds ubiquitinated-RIP1, limiting FADD and caspase-8 recruitment.
• High ANKRD13a expression inversely correlates with apoptosis and predicts poor prognosis in ovarian cancer.

Conclusions:

• ANKRD13a is a novel gatekeeper of the early cell-death checkpoint in TNF signaling.
• ANKRD13a functions as a tumor suppressor by preventing excessive cell death.
• ANKRD13a may represent a therapeutic target for overcoming resistance to cell death in cancers.